Pagina inicial
Continue Watching
Últimos vídeos
Últimos vídeos
Brightcove Home Latest Listing
Oncology
Oncology
Brightcove Cards Listing
Hematology
Hematology
Brightcove Cards Listing
Popular em MedEnrich
Popular em MedEnrich
Popular in Sem nome
- Myelodysplastic Syndromes23m 43s
Desenvolvimento e Atualizações na Biologia das Mielodisplasias
Desenvolvimento e Atualizações na Biologia das Mielodisplasias (MDS)síndromes mielodisplásicas mds avanços na biologia terapias inovadoras epidemiologia da mds - Oncospecials15m 30s
A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais
ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.oncologia ccr câncer renal tki sunitinibe - Mieloma múltiplo9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.pomalidomide-dexamethasone rrmm management progression-free survival combination therapies - Câncer de próstata6m 59s
Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPCnmcrpc metastasis free survival spartan prosper & aramis clinical trial - Myelodysplastic Syndromes14m 13s
ASH 2022 Update on Myelodysplastic Syndromes
ASH 2022 - Update on Myelodysplastic Syndromeslow risk mds venetoclax viale -a eln classification low dose lenalidomide tags: azacitidine - 3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.her2 positive mbc prolonged remission trastuzumab duration - Mieloma múltiplo17m 14s
Tratamento do mieloma múltiplo
Tratamento do mieloma multiplo_Dr Ederson Mattosmm mieloma múltiplo tratamento lenalidomida nccn ederson mattos - Acute Myeloid Leukaemia12m 22s
EHA 2022 Updates : AML
EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with addition of quizartinib to standard induction and consolidation therapy alone.aml decitabine g-csf hypomethylating agents - 3m 56s
Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission
There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.her2 positive mbc prolonged remission trastuzumab duration - 11m 28s
ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer
ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.aromatase inhibitor resistance hr +ve mbc esr1 mutation fulvestrant
- 1
Desenvolvimento e Atualizações na Biologia das...
- 2
A Relevância dos Agentes TKI na era das...
- 3
Integrating Pomalidomide Based Regimens in Multiple...
- 4
Managing Nonmetastatic Castration-Resistant...
- 5
ASH 2022 Update on Myelodysplastic Syndromes
- 6
Duration of trastuzumab in patients with Her2...
- 7
Tratamento do mieloma múltiplo
- 8
EHA 2022 Updates : AML
- 9
Duration of trastuzumab in patients with Her2...
- 10
ESR1 Mutation in Hormone Receptor Positive Advanced...